Avidity Biosciences spun its preclinical cardiac RNA programs into Atrium Therapeutics with roughly $270 million in cash and equivalents to back two AOC-based candidates for rare genetic cardiomyopathies. Atrium named lead candidates ATR-1072 (PRKAG2 syndrome) and ATR-1086 (PLN cardiomyopathy) and plans IND filings beginning in the second half of the year. Separately, Vima Therapeutics expanded its Series A to $100 million and extended its pipeline to include Parkinson’s disease after early proof-of-concept data in isolated dystonia. Vima told investors it sees potential across multiple movement disorders and will use proceeds to accelerate clinical development. Both transactions highlight growing investor appetite for precision RNA platforms and oral small-molecule approaches in neurology and cardiology, and they underscore a trend of spinning specialized programs into focused companies with dedicated financing to de-risk modality- and target-specific development.